Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMT101 and Irinotecan with SG001 in mCRC
NCT06089330Phase 2Not yet recruiting
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- Jan 2024
- Primary completion
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
A Phase 2 trial of becotatug in metastatic colorectal cancer (mCRC), sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
becotatug
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT06089330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06089330.